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Abstract
Background: Several fluorine-18 labelled fluoroamino acids have been evaluated as tracers for the
quantitative assessment of cerebral protein synthesis in vivo by positron emission tomography
(PET). Among these, 2-[18F]fluoro-L-tyrosine (2-[18F]Tyr) has been studied in mice at a low specific
activity. Its incorporation into proteins is fast and metabolism via other pathways is limited. The
present in vivo study was carried out in normal awake rats using no-carrier-added 2-[18F]Tyr. Under
normal physiological conditions, we have studied the incorporation into proteins and the
metabolism of the tracer in different brain areas.
Methods: No-carrier-added 2-[18F]Tyr was administered to awake rats equipped with chronic
arterial and venous catheters. The time course of the plasma activity was studied by arterial blood
sampling. The biodistribution of the activity in the main organs was studied at the end of the
experiment. The distribution of radioactive species in plasma and brain regions was studied by
acidic precipitation of the proteins and HPLC analysis of the supernatant.
Results: The absolute uptake of radioactivity in brain regions was homogenous. In awake rats, no-
carrier-added 2-[18F]Tyr exhibits a fast and almost quantitative incorporation into the proteins
fractions of cerebellum and cortex. In striatum, this incorporation into proteins and the unchanged
fraction of the tracer detected by HPLC could be lower than in other brain regions.
Conclusion: This study confirms the potential of 2-[18F]fluoro-L-tyrosine as a tracer for the
assessment of the rate of protein synthesis by positron emission tomography. The observed
metabolism suggests a need for a correction for the appearance of metabolites, at least in plasma.
Background
For years, amino acids, the basic units of proteins, have
been identified as a potential tool for the study of the in
vivo cellular kinetics of protein synthesis [1]. In order to
achieve this in humans, implementing nuclear medicine
applications, researchers must make use of either radioac-
tive forms of natural amino acids or radioactive analogues
which can be incorporated into proteins.
Although radioactive iodinated derivatives have been
studied for single photon emission computed tomogra-
phy (SPECT) and are still of particular interest today [2],
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compounds labelled with positron emitters, suitable for
the positron emission tomography (PET), were the main
subjects of study in human functional imaging for the last
twenty years. This relies on the high sensitivity and the
quantitative capability of PET [3] and on the characteris-
tics of carbon-11, an isotope of a naturally existing ele-
ment in biological molecule, or fluorine-18, a bioisostere
of naturally existing chemical groups, for example the OH
group [4,5].
L-[S-methyl-11C]-methionine has been used to generate
interesting clinical results for the diagnosis of brain
tumours [6]. Unfortunately, due to the very short half-life
of carbon-11 (20.4 minutes), the use of tracers labelled
with this radionuclide is logistically only possible on sites
equipped with their own cyclotron. Even in this case, the
completion of a high number of patient examinations
with the same radiopharmaceutical batch is technically
difficult except if several PET scanners are simultaneously
accessible. This physical limitation therefore restricts the
usefulness of carbon-11 labelled tracers in the study of
biochemical processes to a time scale of maximum one
hour.
With a half-life of 109.8 minutes, fluorine-18 presents
better characteristics for the geographic expansion of radi-
opharmaceuticals supply. This capability has been practi-
cally proven worldwide with the use of the PET tracer 2-
[18F]fluoro-deoxyglucose ([18F]FDG). Moreover, the
longer half-life of fluorine-18 is more suitable for the
study of processes with a time scale of more than one
hour, such as brain protein synthesis by example.
The fluorinated aromatic amino acids 2-, 3- and 4- fluor-
ophenylalanine, 2- and 3- fluorotyrosine (figure 1) have
been described by geneticists as potential surrogates for
canonical phenylalanine and tyrosine in an expanded rep-
ertoire of amino acids corresponding to a less restricted
genetic code [7]. All of them have been previously been
evaluated as [18F] labelled tracers for the quantitative
assessment of cerebral protein synthesis in vivo [8]. 2-
[18F]fluorophenylalanine and 2-[18F]fluorotyrosine have
also been considered for application in tumour imaging
[9].
Among the few fluorinated amino acids incorporated into
proteins, 2-[18F]fluoro-L-tyrosine (2-[18F]Tyr) is the most
promising. Its incorporation has been studied in mice at a
low specific activity (10–20 GBq/mmol). This revealed a
very simple metabolism as well as rapid incorporation
into proteins [10].
The present in vivo study was carried out in awake rats
using no-carrier-added (n-c-a) 2-[18F]Tyr, under normal
physiological conditions. The incorporation of this tracer
into proteins and its metabolism were studied. The use of
a tracer with higher specific activity increases the sensitiv-
ity for the detection of potential biochemical mecha-
nisms, in which the fluorinated analogue could
specifically be involved, in comparison to the natural cir-
culating amino acid.
Methods
3-O-methyl-6-fluorodopa (3-OMFD), 3,4-dihydroxy-6-
fluorophenylacetic acid (FDOPAC), 6-fluorodopamine
(FDA) and 6-fluorohomovanillic acid (FHVA) were syn-
thesized following previously published procedures [11].
2-fluoro-L-tyrosine and 6-fluoro-L-dopa were purchased
from SanverTech. The n-c-a 2-[18F]Tyr used in this work
was obtained through two different enantioselective
methods of synthesis previously published by Lemaire
[12,13]. The first was described for 6-[18F]fluoro-L-dopa
and adapted for 2-[18F]fluoro-L-tyrosine from 4-methoxy-
2- trimethylammoniumbenzaldehyde triflate and (2S)-1-
tert-boc-2-tert-butyl-3-methyl-4-imidazolidinone. The
second uses catalytic phase-transfer alkylation with a chi-
ral quaternary ammonium salt derived from a Cinchona
alkaloid. The enantiomeric purity and the specific activity
were controlled at the end of synthesis and were above
95% and 37 GBq/μmol respectively.
All animal experiments were approved by the Ethical
Committee at our institution. Chronic cannulations of
rats (male, Sprague Dawley, 180–250 g) were performed
in the abdominal aorta and in the vena cava under general
anaesthesia (ketamine 35 mg/kg and medetomidin 0.35
mg/kg) following the procedure described by Lestage [14].
The animals were allowed to recover for a minimum of 4
Structure of fluorinated aromatic amino acids Figure 1
Structure of fluorinated aromatic amino acids. 2-
fluoro-L-phenylalanine (R2 = F, R3 = R4 = H); 3-fluoro-L-
phenylalanine (R3 = F, R2 = R4 = H); 2-fluoro-L-tyrosine (R2 
= F, R3 = H, R4 = OH), 3-fluoro-L-tyrosine (R3 = F, R2 = H, 
R4 = OH); 4-fluoro-L-phenylalanine (R2 = R3 = H, R4 = F).BMC Medical Physics 2008, 8:4 http://www.biomedcentral.com/1756-6649/8/4
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days before being used for metabolism studies. Most of
them were injected with the tracer within the first week
after surgery. Some of them were kept up to 4 weeks
before injection. Twenty hours before the injection of the
tracer, the food was removed from the cage. The arterial
line was used for blood sampling and the other for i.v.
injection of the tracer. The two lines were flushed with
saline a few minutes before use in order to check potency.
14 rats (230–410 g) were injected with 20–325 MBq of n-
c-a 2-[18F]Tyr. The tracer was delivered as a bolus of max-
imum volume 0.75 ml in 15 s. Samples of blood were
obtained via the arterial cannula during the first minutes
after the injection and at different times (15, 30, 45, 60
and/or 90 minutes) thereafter. The line was flushed with
saline between each sample to avoid any loss of potency
and to ensure the homogeneity of the next sample. The
animals (n = number of rats) were sacrificed after 30 (n =
2), 60 (n = 5), 90 (n = 3) or 120 (n = 4) minutes. After the
final time point, samples of blood were taken and the
major organs were dissected. The brain was dissected to
obtain striatum, cortex and cerebellum.
Trichloroacetic acid (TCA) was used to precipitate the pro-
teins from biological samples in order to assay the radio-
active content associated with proteins and to perform a
chromatographic analysis of the radioactive compounds
in solution in the supernatant after centrifugation. The
solution used for the precipitation was Na2S2O5 100 mg,
NaEDTA.2H2O 10 mg, TCA 20 g, dissolved in water up to
100 ml.
Radioactivity was measured in weighed fractions of
plasma. For intermediate and final plasma samples, pro-
teins were precipitated with TCA solution and separated
by centrifugation (5°C, 5 minutes, 8000 RPM) before
counting. The supernatant was analysed by HPLC. Radio-
activity was measured in the organ samples and in one
half of the three dissected parts of the brain. The second
halves were sonicated with water (Sonics & Materials inc.,
Vibracell VXC-400). The proteins were precipitated with
TCA solution and separated by centrifugation (5°C, 5
minutes, 8000 RPM) before counting. The supernatant
was analysed by HPLC.
The metabolites analysis was performed by HPLC [11] on
fractions of the supernatants obtained after precipitation
and centrifugation. Column: Phenomenex Bondclone 10
μm C18 300 mm × 3.9 mm. Injection volume: 100 μl.
Mobile phase: 80% of 0.1 M NaH2PO4, 0.1 mM EDTA, 2.6
mM octane sulfonic acid sodium salt and 20% methanol,
pH 3.1. The flow rate was 1 ml/min from start to 8 min-
utes and was then increased in 30 seconds interval at 1.5
ml/min. Fractions of 30 seconds were collected for 16
minutes. Capacity factors: FDOPA: 0.8; 3-OMFD: 1.5;
FTYR: 1.9; FDOPAC: 2.6; FDA: 3.3; FHVA: 5.0 (k' = tr-t0 /
t0, tr: retention time of the solute, t0: column dead time).
Radioactivity measurements of the biological samples and
of the fractions collected during HPLC were performed
with a NaI counter (Cobra II autogamma, Packard).
Results
Biodistribution
The biodistribution of n-c-a 2-[18F]Tyr after injection,
expressed as the percentage of the injected activity recov-
ered per gram of tissue (%IA/g) at different times is pre-
sented in table 1 [see Additional file 1]. The values
observed for different regions of the brain (cerebellum,
striatum and cortex) are presented in table 2 [see Addi-
tional file 2], column "total". Most of the tissues under-
went a rapid uptake of activity without major evolution
after 30 minutes. In particular, brain and brain sub-
regions had very similar and stable uptakes. In plasma and
bone uptake increased with time.
Metabolism of the tracer
In the radioactive pool observed in the different tissues,
the distribution of the radioactive species was studied by
precipitation with TCA (precipitated fraction, proteins)
and by HPLC analysis of the supernatant (unchanged
tracer fraction). The %IA/g recovered in the precipitated
fraction was calculated from the counts in these fractions.
The percentage of unchanged tracer in the fractions col-
lected by HPLC was calculated from the counts in these
fractions and used to calculate the percentage of the
injected activity recovered unchanged per gram of tissue
in the supernatant fraction. This distribution of radioac-
tive species is presented at different times for plasma, cer-
ebellum, striatum and cortex (table 2 [see Additional file
2]). For plasma, table 3 [see Additional file 3] includes the
measured percentages of activity associated with proteins
in the total activity and with the unchanged fraction in
supernatant obtained after proteins precipitation. This
table also includes the calculated values for the
unchanged fraction in the total activity and the remainder
(100 – % of proteins in total- % of unchanged in total).
Although the numbers of observations are small in most
time points, some tendencies can be qualitatively extrap-
olated from these data. The incorporation into proteins
was the most important metabolism observed for the
tracer. This incorporation was rapid and reached high val-
ues already at 60 minutes. The transformation of the tracer
into the catecholamine derivatives was a secondary proc-
ess with very low quantitative importance. When compar-
ing in table 2 [see Additional file 2] the values of the % IA/
g associated with proteins for cerebellum and striatum,
the data suggest that the incorporation seemed to be less
important for striatum.BMC Medical Physics 2008, 8:4 http://www.biomedcentral.com/1756-6649/8/4
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Input function
The average values of plasma activity over time were cor-
rected for the global appearance of metabolites (TCA pre-
cipitated and soluble) with the values of percentages of
the total activity recovered unchanged (table 3 [see Addi-
tional file 3]) to obtain the kinetics of total arterial plasma
activity after injection of n-c-a 2-[18F]Tyr (figure 2). In this
figure, the points for times before 15 minutes represent
the observed values for one rat only and are not corrected.
This part of the figure shows an example plasma profile of
total activity after the intravenous injection. From 15 min-
utes, all values are the average of n observations (table 3
[see Additional file 3]) with or without correction for the
transformation of the tracer. The plasma input function
obtained clearly shows an increasing contribution of the
protein pool over time, after the initial peak of injection.
Discussion
During the last years, fluorinated tracers [15], especially
amino acids [9], were mainly studied for their application
in tumour imaging. A major aim of these developments is
to improve, in comparison with the routine [18F]FDG
scan, the specificity for tumours and the contrast with the
surrounding tissues, especially in brain cancers. For this
purpose, nuclear imaging is based on the ability of the
tumour cells to concentrate amino acids more than nor-
mal tissues as a result of an increased efficiency of the
transport through the cellular membrane by active trans-
port systems. Moreover, the increased proliferation rate in
tumours goes together with a higher protein synthesis rate
(PSR). Thus, for some labelled amino acids, characterised
by their capability to be incorporated into proteins,
increased transport is coupled to a subsequent incorpora-
tion step. The two steps are kinetically different. Transport
is a relatively rapid process allowing imaging only 20 min-
utes after injection. Incorporation into proteins is a slower
process that requires imaging at longer times post-injec-
tion. This represents an advantage in the use of fluorine-
18 rather than carbon-11 for PET evaluation of PSR.
Different parameters, including amino acid transport and
PSR, are needed to fully characterise a tumour and moni-
tor the response to treatments [9]. An incorporated
labelled amino acid has the advantage of potentially
imaging, with a single injection, either early transport of
amino acids into cells and the delayed incorporation into
Input function Figure 2
Input function. Kinetics of total arterial plasma activity with and without correction for appearance of metabolites. Values for 
times less than 15 minutes are uncorrected measured values for one rat (early, full squares). Open squares represent the aver-
age of all measures of uncorrected %IA/g of plasma. Full triangles represent the average values corrected for the appearance of 
metabolites using percentages reported in table 3. Insert: zoom on early times.BMC Medical Physics 2008, 8:4 http://www.biomedcentral.com/1756-6649/8/4
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the proteins afterwards. Nevertheless, this may only be a
virtual advantage for tumour imaging as some studies
indicate that the major phenomenon leading to an
increased uptake of amino acids in tumors is an enhance-
ment of amino acid transport rather than an increased
PSR. So, the uptake of L-[S-methyl-11C]methionine in
mice brain was not influenced by the use of a inhibitor for
protein synthesis [16]. In the same conditions, the uptake
of 2-[18F]Tyr was partially reduced. In another study eval-
uating 2-[18F]Tyr in patients with gliomas [17], pharma-
cokinetic modelling of the results indicated that the main
difference between normal and tumorous tissues was a
significantly increased transport rate constant from
plasma to tissue. Thus, these two studies suggested that 2-
[18F]Tyr could be used to assess the amino acid transport
system. In this context, more recent developments have
led to the evaluation of O-(2-[18F]Fluoroethyl)-L-tyrosine.
This tracer, not incorporated into proteins, has the impor-
tant advantage of being available with a relatively high
radiochemical yield (40%) allowing the distribution of
the product and its use to a larger extent. As a result of this
availability, it has already been evaluated for different
applications in clinical oncology [18]. In comparison, 2-
[18F]Tyr suffers from a less efficient radiosynthesis and
must thus still be better evaluated. In a small study for
whole-body tumour imaging, the tracer was less sensitive
than [18F]FDG for staging NSCLCs and lymphomas [19].
In another study focusing on primary brain tumors, 2-
[18F]Tyr allowed a better tumor to background contrast in
low-grade gliomas [20].
In addition to neuroendocrine activity, nucleic acid syn-
thesis and gene transcription, protein synthesis has been
described as a potential basic mechanism for brain synap-
tic plasticity [21]. Thus, incorporated amino acids may
have further advantages for the study of various non
tumourous processes. For example, the evaluation of PSR
during brain development, sleep or memory consolida-
tion is only possible with an incorporated tracer. Thus,
beside uses in oncology, imaging PSR with amino acids
presents a real interest for functional research, as well as
potential applications in pathologies related to neurolog-
ical physiological processes. The use of a single pharma-
ceutical agent adapted for several applications is a good
approach from an economical point of view. As markedly
demonstrated by [18F]FDG, this is especially true for PET
pharmaceuticals, whose constraints concerning logistics,
radioprotection and quality assurance, are considerable.
All these arguments are in favour of the development of a
multi-purpose [18F] fluorinated incorporated amino acid.
2-[18F]Tyr was identified early by Coenen and colleagues
[10] as a promising tracer for PSR assessment in an exten-
sive study in mice. At a low specific activity, its acceptance
by the amino acid-tRNA synthetase has been proven by
phenolic extraction of the tRNA bound fraction. The rapid
and general incorporation into proteins has been con-
firmed by SDS gel electrophoresis. A very small propor-
tion of metabolites was detected in striatum tissue and the
authors raised the possibility of a very small entrance of
the tracer to the catecholamine metabolic pathway [22].
The present study was performed using n-c-a 2-
[18F]fluoro-L-tyrosine allowing the injection of a high
amount of radioactivity (up to 325 MBq) supported by a
low amount of non radioactive equivalent (less than 10-2
μmole). The higher specific activity used in this study may
not be of major physiological consequence since the con-
centration of competing amino acids in the plasma is high
under fasting conditions. On the other hand, one can not
exclude the existence of a biochemical mechanism (e.g.
transport or metabolism) truly specific for the fluorinated
analogue, in which the non fluorinated natural amino
acid could not be involved at all. Using a higher specific
activity increases the sensitivity for the detection of these
potential mechanisms. The results of the present study can
thus be interestingly compared to the results published for
mice [10].
From the biodistribution data presented in table 1 [see
Additional file 1], we can observe that the fluorinated ana-
logue rapidly passes the blood-brain-barrier as the uptake
in brain already reached a high value at only 30 minutes
post injection. The absolute uptake into rat brain tissue
(~0.15%IA/g) was lower than the value reported for mice
(~1.3%IA/g at 40 min.; ~2%IA/g at 60 min.), as may be
expected due to species differences (including size, weight
and distribution volume). On the other hand, the total
radioactivity of the plasma increased with time after the
initial peak of injection, indicating the elimination of
radioactive compounds in the blood. The uptake of radi-
oactivity in bone increased with time and to a greater
degree than in other organs such as muscle, heart or lung,
indicating the probable liberation of [18F]F-during the
metabolism of the tracer. The comparison of uptake in the
different brain regions shows a homogeneous distribu-
tion of activity (table 2 [see Additional file 2]).
In all studied tissues, the radioactivity associated with pro-
teins increased from 30 minutes to 120 minutes (table 2
[see Additional file 2]). Expressed as the percentage of the
total activity in the tissue, this fraction at 60 minutes in rat
cerebellum and cortex (respectively 84% and 85%)
matches the reported value for mouse cortex (84%). In
rats, the incorporation in non dopaminergic rich regions
reaches almost 90% of the total activity at 120 minutes.
On the other hand, the observed incorporation of tracer in
the striatum may be less than in other brain regions (66%
at 60 min.). This tendency should be confirmed by a more
extensive study including a higher number of subjects andBMC Medical Physics 2008, 8:4 http://www.biomedcentral.com/1756-6649/8/4
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allowing accurate statistical evaluation of the observa-
tions.
The percentage of unmetabolised 2-[18F]Tyr in the super-
natant after protein precipitation decreased with time in
all tissues, indicating that the tracer enters another path-
way that simply the incorporation into proteins. This per-
centage of unchanged 2-[18F]Tyr was smaller in the
striatum at all time points, indicating that a fraction prob-
ably enters the catecholamine metabolic chain. These
observations are compatible with the affirmation that 2-
[18F]Tyr is a substrate for the enzyme tyrosine hydroxy-
lase. A strict identification and a precise quantification of
the metabolites require an improved methodology to con-
centrate the solutes before HPLC analysis. Nevertheless,
radioactive compounds corresponding to products eluted
before 2-[18F]Tyr (as FDOPA does) and after (as FDA and
FHVA do), were observed for the striatum.
In our laboratory, the enantioselective synthesis of n-c-a
2-[18F]Tyr is now routinely performed by chiral phase-
transfer alkylation [13]. This synthesis proceeds via the
preparation of a [18F] labelled electrophilic agent, fol-
lowed by alkylation and hydrolysis before HPLC purifica-
tion. The radiochemical yield averages 25% (decay-
corrected, 100 minutes). Although very good enantio-
meric excesses can be obtained, this method suffers from
a long duration and some steps are difficult to automate
(bromination with gaseous HBr for example). Thus, it is
crucial that the method be further improved in order to
permit higher yields through a completely automatable
pathway, as is already the case for some other fluorinated
amino acids, such as O-(2-[18F]Fluoroethyl)-L-tyrosine
[18].
Conclusion
This study of the metabolism of 2-[18F]fluoro-L-tyrosine
in rats confirms that this tracer is rapidly and extensively
incorporated into cerebral proteins and is therefore well
suited to the assessment of PSR in vivo by PET. A correction
for the appearance of metabolites is advised for quantita-
tive interpretation of the collected data at least in plasma.
An improvement in the radiosynthesis is necessary to
make 2-[18F]Tyr widely available for its application in
oncology and to envisage the extended use of this multi-
purpose tracer.
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